The independent platform for news, articles and advice for professionals in laboratory medicine

Getting cancer services back on track: a diagnostics sector role

Healthcare leaders are calling upon government and health providers to drastically scale-up and improve cancer services in the wake of the SARS-CoV-2 pandemic. This article provides an insight into some of the key recommendations for a recovery.

Nearly half of people who experienced possible cancer symptoms in the first wave of the SARS-CoV-2 pandemic did not contact their GP, according to research carried out by Cardiff University and Cancer Research UK, published early this year. The findings focused on the experiences of 7543 people from March to August 2020.1

        Possible cancer symptoms were commonly experienced during the first wave, the survey found, with 40.1% of participants (3025 people) saying they had experienced at least one potential symptom. Of those who experienced symptoms, a substantial proportion (44.8%) reported not contacting their GP for any symptom, even for red flags such as coughing up blood (30.7% of those who experienced this symptom did not seek help), an unexplained lump or swelling (41% did not seek help) or a change in the appearance of a mole (58.6% did not seek help). Principal investigator Professor Kate Brain, a health psychologist from Cardiff University’s School of Medicine, said people had “put their health concerns on hold to protect the NHS”.

        A significant number were concerned about ‘wasting healthcare professionals’ time’ (15.4%), others worried about putting extra strain on the NHS (12.6%) or being seen as ‘someone who makes a fuss’ (12%), some reported difficulty with access to healthcare services (10.3%), while around 9.6% worried about catching coronavirus.

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.
Register

Upcoming Events

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5th - 6th June 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

UK NEQAS Blood Coagulation: Clinical and Laboratory Haemostasis 2024

Sheffield Hallam University
5th - 6th June 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025